Melanoma trials in Germany

In Germany 49 Also abroad 579

49 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Where
Berlin, Dresden, Erfurt, Essen, Frankfurt Am Main, Hamburg, Heidelberg, Kiel, Mainz, Munich, Tuebingen
Age
12 years and over
People
400 worldwide
Run by
Replimune, Inc.
See details and how to joinNCT06264180 · EU 2023-508612-29-00
No phaseTaking people
Reducing Symptom Burden Through Physical Exercise in Melanoma Patients
Where
Essen
Age
18 years and over
People
86
Run by
Universität Duisburg-Essen
See details and how to joinNCT06985056
Phase 1/2Taking people
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Where
Muenster, Tuebingen
Age
6 months to 17 years
People
370 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT02332668 · EU 2022-501257-36-00
Phase 3Taking people
Adjuvant Tebentafusp in High Risk Ocular Melanoma
Where
Berlin, Essen, Hamburg, Heidelberg
Age
18 years and over
People
290 worldwide
Run by
European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT06246149 · EU 2023-510333-28-00
Phase 1/2Taking people
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Where
Berlin, Bonn, Dresden, Hamburg, Heidelberg, Mainz, Munich, Würzburg
Age
18 years and over
People
375 worldwide
Run by
Immatics US, Inc.
See details and how to joinNCT03686124
Phase 3Taking people
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Where
Berlin, Bonn, Dessau-Rosslau, Erlangen, Essen, Luebeck, Marburg, Muenster, Tuebingen, Ulm, Wuerzburg
Age
18 years and over
People
520 worldwide
Run by
IDEAYA Biosciences
See details and how to joinNCT07015190 · EU 2025-522387-32-00
No phaseTaking people
Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma
Where
Hamburg
People
40
Run by
Universitätsklinikum Hamburg-Eppendorf
See details and how to joinNCT07564570
Phase 1/2Taking people
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Where
Bonn, Erlangen, Essen, Hamburg, Heilbronn
Age
18 years and over
People
240 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06413680 · EU 2025-523399-22-00
Phase 2/3Taking people
DICIT: Efficacy of diclofenac added to an approved, ongoing PD-1 inhibitor therapy that achieved stable disease as best response in metastatic melanoma patients. A single arm phase II trial
Where
Essen, Halle (Saale), Mainz, Regensburg
Age
18 years and over
People
48
Run by
Universitaetsklinikum Regensburg
See details and how to join2023-504191-26-00 · EU 2023-504191-26-00
Phase 2/3Taking people
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Where
Berlin, Hamburg, Heidelberg
Age
18 years and over
People
280 worldwide
Run by
Replimune, Inc.
See details and how to joinNCT06581406 · EU 2023-508784-68-00
Phase 3Taking people
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Where
Berlin, Cologne, Dresden, Erlangen, Essen, Hamburg, Heidelberg, Kiel, Minden, Munich, Tuebingen
Age
18 years and over
People
540 worldwide
Run by
Immunocore Ltd
See details and how to joinNCT05549297 · EU 2022-502732-39-00
Phase 3Taking people
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Where
Berlin, Bremen, Dortmund, Dresden, Erfurt, Erlangen, Essen, Frankfurt, Giessen, Hamburg, Heidelberg, Kiel, Leipzig, Mainz, Marburg, Minden, Munich, Tübingen, Würzburg
Age
18 years and over
People
680 worldwide
Run by
Immunocore Ltd
See details and how to joinNCT06112314
Phase 4Taking people
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
Where
Heidelberg, Munich
Age
18 years and over
People
50 worldwide
Run by
Replimune, Inc.
See details and how to joinNCT06887348 · EU 2025-521621-33-00
No phaseTaking people
Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
Where
Frankfurt
Age
18 years and over
People
45
Run by
Goethe University
See details and how to joinNCT07161310
Phase 3Taking people
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
Where
Augsburg, Berlin, Dresden, Essen, Freiburg im Breisgau, Heidelberg, Kiel, Leipzig, Tuebingen
Age
18 years and over
People
186 worldwide
Run by
Philogen S.p.A.
See details and how to joinNCT03567889 · EU 2023-507119-36-00
No phaseNot yet taking people in Germany
Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
Where
Heidelberg
Age
18 years and over
People
600 worldwide
Run by
OncoHost Ltd.
See details and how to joinNCT07246759
No phaseTaking people
Video-Tumorboard PLUS
Where
Bonn, Dresden, Münster
Age
18 years and over
People
300
Run by
University Hospital Muenster
See details and how to joinNCT06980740
No phaseTaking people
Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy.
Where
Heidelberg, München, Tübingen
Age
18 years and over
People
196
Run by
Pamgene International B.V.
See details and how to joinNCT06784778
No phaseTaking people
The Study Aims to Measure the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography and to Analyse Differences Depending on the Course of the Disease.
Where
Dresden
Age
18 years and over
People
3,000
Run by
Technische Universität Dresden
See details and how to joinNCT06765850
Phase 1/2Taking people
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
Where
Tuebingen
Age
18 years and over
People
96 worldwide
Run by
The Netherlands Cancer Institute
See details and how to joinNCT06240143 · EU 2023-505945-19-00
No phaseTaking people
Artificial Intelligence Based Melanoma Early Diagnosis and Risk Prediction in Children, Adolescents and Young Adults
Where
Tübingen
People
3,000 worldwide
Run by
German Cancer Research Center
See details and how to joinNCT06621810
No phaseTaking people
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
Where
Hamburg
Age
18 years and over
People
200 worldwide
Run by
European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04498767
Phase 2Taking people
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Where
Essen, Heidelberg
Age
18 years and over
People
60 worldwide
Run by
IO Biotech
See details and how to joinNCT05280314
No phaseTaking people
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
Where
Ahaus, Aschaffenburg, Augsburg, Berlin, Bremerhaven, Buxtehude, Chemnitz, Donauwörth, Dresden, Duisburg, Erfurt, Essen, Gera, Giessen, Goslar, Göttingen, Hamburg, Hanover, Heidelberg, Karlsruhe, Kiel, Landshut, Leipzig, Lübeck, Ludwigshafen, Magdeburg, Mainz, Mannheim, Marburg, Minden, München, Münster, Nuremberg, Regensburg, Schorndorf, Schwerin, Stolberg, Trier, Tübingen, Zwickau
Age
18 years and over
People
750 worldwide
Run by
Pierre Fabre Pharma GmbH
See details and how to joinNCT04045691